{"transactions":[{"id":714869,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-07-07T00:40:23.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":7700,"price":5.69,"value":43813.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market."}],"balance_after":55807,"source":{"system":"sec-edgar","filing":"0001493152-26-032235","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000149315226032235/ownership.xml","form_type":"4"}},{"id":715167,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-07-07T00:38:00.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":7700,"price":5.69,"value":43813.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 35,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market."}],"balance_after":58752,"source":{"system":"sec-edgar","filing":"0001493152-26-032233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000149315226032233/ownership.xml","form_type":"4"}},{"id":715135,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-07-07T00:35:43.000Z","date":"2026-07-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":12100,"price":5.69,"value":68849.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reported disposition reflects shares withheld by the Issuer to cover tax withholding obligations in connection with the vesting of 55,000 shares of restricted stock units granted to the reporting person on July 1, 2025. The reporting person did not sell any shares. The per-share value assigned to the shares withheld reflects the price per share on the date on which the shares vested as reported on the Nasdaq Capital Market."}],"balance_after":156785,"source":{"system":"sec-edgar","filing":"0001493152-26-032231","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315226032231/ownership.xml","form_type":"4"}},{"id":737624,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-06-15T22:22:12.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":26943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date."}],"balance_after":63507,"source":{"system":"sec-edgar","filing":"0001493152-26-028755","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000149315226028755/ownership.xml","form_type":"4"}},{"id":737746,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-06-15T22:22:07.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":26943,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date."}],"balance_after":66452,"source":{"system":"sec-edgar","filing":"0001493152-26-028754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000149315226028754/ownership.xml","form_type":"4"}},{"id":737740,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-06-15T22:22:01.000Z","date":"2026-06-11","kind":"grant","planned":false,"acquired":true,"shares":32331,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest on the date of the next annual meeting of shareholders, subject to the Reporting Person's continued service from the date of grant until the vesting date."}],"balance_after":168885,"source":{"system":"sec-edgar","filing":"0001493152-26-028753","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315226028753/ownership.xml","form_type":"4"}},{"id":799982,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-27","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12684884,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":799981,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-27","kind":"purchase","planned":false,"acquired":true,"shares":250923,"price":3.6391,"value":913133.8893,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This constitutes the weighted average purchase price. The prices range from $3.50 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12684884,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":799980,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-24","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12433961,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":799979,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-24","kind":"purchase","planned":false,"acquired":true,"shares":38880,"price":3.5258,"value":137083.104,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This constitutes the weighted average purchase price. The prices range from $3.47 to $3.59. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12433961,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":799978,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-23","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12395081,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":799977,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-27T23:08:17.000Z","date":"2026-04-23","kind":"purchase","planned":false,"acquired":true,"shares":280381,"price":3.5025,"value":982034.4525,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This constitutes the weighted average purchase price. The prices range from $3.39 to $3.54. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the \"SEC Staff\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12395081,"source":{"system":"sec-edgar","filing":"0000919574-26-002414","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002414/ownership.xml","form_type":"4"}},{"id":804368,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12114700,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":804367,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":40690,"price":3.8822,"value":157966.718,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This constitutes the weighted average purchase price. The prices range from $3.75 to $3.99. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12114700,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":804366,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-17","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12074010,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":804365,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-17","kind":"purchase","planned":false,"acquired":true,"shares":40114,"price":3.5711,"value":143251.1054,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This constitutes the weighted average purchase price. The prices range from $3.45 to $3.84. The Reporting Person will provide upon request by the SEC Staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12074010,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":804364,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12033896,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":804363,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-04-20T23:24:03.000Z","date":"2026-04-16","kind":"purchase","planned":false,"acquired":true,"shares":102057,"price":3.4457,"value":351657.8049,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This constitutes the weighted average purchase price. The prices range from $3.20 to $3.59. The Reporting Person will provide upon request by the Securities and Exchange Commission staff (the \"SEC Staff\"), the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":12033896,"source":{"system":"sec-edgar","filing":"0000919574-26-002306","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426002306/ownership.xml","form_type":"4"}},{"id":825069,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Restricted Stock Units","published_at":"2026-03-30T21:29:07.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":6289,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU has a value equal to one share of common stock. 33 and 1/3% of the RSUs vested on March 26, 2026 and the remaining 66 and 2/3% will vest in equal installments on each of the second- and third-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 33 and 1/3% of the RSUs vested on March 26, 2026 and the remaining 66 and 2/3% will vest in equal installments on each of the second- and third-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 33 and 1/3% of the RSUs vested on March 26, 2026 and the remaining 66 and 2/3% will vest in equal installments on each of the second- and third-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":12578,"derivative":{"underlying":"Common Stock","underlying_shares":6289},"source":{"system":"sec-edgar","filing":"0001493152-26-013572","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226013572/ownership.xml","form_type":"4"}},{"id":825068,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Common Stock","published_at":"2026-03-30T21:29:07.000Z","date":"2026-03-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":2578,"price":4.11,"value":10595.58,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares."}],"balance_after":3711,"source":{"system":"sec-edgar","filing":"0001493152-26-013572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226013572/ownership.xml","form_type":"4"}},{"id":825067,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Common Stock","published_at":"2026-03-30T21:29:07.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":6289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents vesting of restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs vested on the one-year anniversary of the effective date of grant."}],"balance_after":6289,"source":{"system":"sec-edgar","filing":"0001493152-26-013572","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315226013572/ownership.xml","form_type":"4"}},{"id":825420,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-30T17:29:10.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":28302,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":84905,"derivative":{"underlying":"Common Stock","underlying_shares":28302},"source":{"system":"sec-edgar","filing":"0001493152-26-013574","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315226013574/ownership.xml","form_type":"4"}},{"id":825419,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T17:29:10.000Z","date":"2026-03-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":11298,"price":4.11,"value":46434.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares."}],"balance_after":206060,"source":{"system":"sec-edgar","filing":"0001493152-26-013574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315226013574/ownership.xml","form_type":"4"}},{"id":825418,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-30T17:29:10.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":28302,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents vesting of restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs vested on the one-year anniversary of the effective date of grant."}],"balance_after":217358,"source":{"system":"sec-edgar","filing":"0001493152-26-013574","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315226013574/ownership.xml","form_type":"4"}},{"id":825386,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2026-03-30T17:29:05.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":false,"shares":47170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU has a value equal to one share of common stock. 25% of the RSUs vested on March 26, 2026 and the remaining 75% will vest in equal installments on each of the second-, third- and fourth-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":141509,"derivative":{"underlying":"Common Stock","underlying_shares":47170},"source":{"system":"sec-edgar","filing":"0001493152-26-013571","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315226013571/ownership.xml","form_type":"4"}},{"id":825385,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-30T17:29:05.000Z","date":"2026-03-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":12310,"price":4.11,"value":50594.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares."}],"balance_after":38365,"source":{"system":"sec-edgar","filing":"0001493152-26-013571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315226013571/ownership.xml","form_type":"4"}},{"id":825384,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock","published_at":"2026-03-30T17:29:05.000Z","date":"2026-03-26","kind":"exercise","planned":false,"acquired":true,"shares":47170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents vesting of restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock. The RSUs vested on the one-year anniversary of the effective date of grant."}],"balance_after":50675,"source":{"system":"sec-edgar","filing":"0001493152-26-013571","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315226013571/ownership.xml","form_type":"4"}},{"id":907313,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-02-13T00:49:56.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":11931839,"source":{"system":"sec-edgar","filing":"0000919574-26-000779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426000779/ownership.xml","form_type":"4"}},{"id":907312,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"Bradsher Neal C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2026-02-13T00:49:56.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":521739,"price":5.75,"value":2999999.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 10, 2026, Broadwood Partners entered into a Securities Purchase Agreement with Insight Molecular Diagnostics, Inc. (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 521,739 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $2,999,999, or $5.75 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":11931839,"source":{"system":"sec-edgar","filing":"0000919574-26-000779","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957426000779/ownership.xml","form_type":"4"}},{"id":1000518,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-11-13T16:34:13.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents vesting an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vested on the last day of the month upon satisfaction of the \"Baby Shelf\" performance condition described in the Reporting Person's Employment Agreement, which required that the Company's public float reach at least $75 million such that the Company would no longer be subject to the SEC's \"baby shelf\" limitations on Form S-3 eligibility. The satisfaction of this condition resulted in the vesting of 50% of the RSUs granted to the Reporting Person, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vested on the last day of the month upon satisfaction of the \"Baby Shelf\" performance condition described in the Reporting Person's Employment Agreement, which required that the Company's public float reach at least $75 million such that the Company would no longer be subject to the SEC's \"baby shelf\" limitations on Form S-3 eligibility. The satisfaction of this condition resulted in the vesting of 50% of the RSUs granted to the Reporting Person, subject to the Reporting Person's continued service."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-25-022358","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225022358/ownership.xml","form_type":"4/A","original_submission_date":"2025-11-04"}},{"id":1000517,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-13T16:34:13.000Z","date":"2025-10-31","kind":"tax_withholding","planned":false,"acquired":false,"shares":12175,"price":6.01,"value":73171.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported disposition reflects shares withheld by the Company to cover required tax withholding obligations upon the vesting of the RSUs. The reporting person did not sell any shares."}],"balance_after":189056,"source":{"system":"sec-edgar","filing":"0001493152-25-022358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225022358/ownership.xml","form_type":"4/A","original_submission_date":"2025-11-04"}},{"id":1000516,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-13T16:34:13.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents vesting an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of common stock."}],"balance_after":201231,"source":{"system":"sec-edgar","filing":"0001493152-25-022358","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225022358/ownership.xml","form_type":"4/A","original_submission_date":"2025-11-04"}},{"id":1008408,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-11-04T16:05:27.000Z","date":"2025-10-31","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vested on the last day of the month upon satisfaction of the \"Baby Shelf\" performance condition described in the Reporting Person's Employment Agreement, which required that the Company's public float reach at least $75 million such that the Company would no longer be subject to the SEC's \"baby shelf\" limitations on Form S-3 eligibility. The satisfaction of this condition resulted in the vesting of 50% of the RSUs granted to the Reporting Person, subject to the Reporting Person's continued service."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vested on the last day of the month upon satisfaction of the \"Baby Shelf\" performance condition described in the Reporting Person's Employment Agreement, which required that the Company's public float reach at least $75 million such that the Company would no longer be subject to the SEC's \"baby shelf\" limitations on Form S-3 eligibility. The satisfaction of this condition resulted in the vesting of 50% of the RSUs granted to the Reporting Person, subject to the Reporting Person's continued service."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-25-020719","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225020719/ownership.xml","form_type":"4"}},{"id":1008407,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-04T16:05:27.000Z","date":"2025-10-31","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents an award of performance-based restricted stock units (\"RSUs\") issued pursuant to the Company's 2018 Equity Incentive Plan. Each RSU represents the right to receive, at settlement, one share of Common Stock."}],"balance_after":201231,"source":{"system":"sec-edgar","filing":"0001493152-25-020719","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225020719/ownership.xml","form_type":"4"}},{"id":1030355,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Option to Purchase Common Stock","published_at":"2025-09-30T21:01:07.000Z","date":"2025-09-28","kind":"grant","planned":false,"acquired":true,"shares":18000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":18000,"derivative":{"exercise_price":3.33,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":18000},"source":{"system":"sec-edgar","filing":"0001493152-25-016360","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315225016360/ownership.xml","form_type":"4"}},{"id":1030681,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2025-09-30T16:57:45.000Z","date":"2025-09-28","kind":"grant","planned":false,"acquired":true,"shares":235000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":235000,"derivative":{"exercise_price":3.33,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":235000},"source":{"system":"sec-edgar","filing":"0001493152-25-016349","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225016349/ownership.xml","form_type":"4"}},{"id":1030646,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Option to Purchase Common Stock","published_at":"2025-09-30T16:05:30.000Z","date":"2025-09-28","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":400000,"derivative":{"exercise_price":3.33,"expiration_date":"2035-09-28","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001493152-25-016291","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315225016291/ownership.xml","form_type":"4"}},{"id":1092084,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-07-03T20:05:34.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":36564,"source":{"system":"sec-edgar","filing":"0001641172-25-017796","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000164117225017796/ownership.xml","form_type":"4"}},{"id":1092286,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-07-03T20:05:25.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":136554,"source":{"system":"sec-edgar","filing":"0001641172-25-017798","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000164117225017798/ownership.xml","form_type":"4"}},{"id":1092292,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-07-03T20:05:22.000Z","date":"2025-07-01","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":39509,"source":{"system":"sec-edgar","filing":"0001641172-25-017787","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000164117225017787/ownership.xml","form_type":"4"}},{"id":1188655,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Restricted Stock Units","published_at":"2025-03-28T20:05:17.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":18867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"33 and 1/3% of the restricted stock units will vest on each of the one-, two- and three-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"33 and 1/3% of the restricted stock units will vest on each of the one-, two- and three-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":18867,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":18867},"source":{"system":"sec-edgar","filing":"0001641172-25-001180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225001180/ownership.xml","form_type":"4"}},{"id":1188654,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP ACCT, Cntlr, Treasurer, PAO"}}],"security":"Option to Purchase Common Stock","published_at":"2025-03-28T20:05:17.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33 and 1/3% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 24 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":3.18,"expiration_date":"2035-03-26","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001641172-25-001180","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000164117225001180/ownership.xml","form_type":"4"}},{"id":1188975,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-03-28T16:05:18.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":113207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the restricted stock units will vest on each of the one-, two-, three- and four-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the restricted stock units will vest on each of the one-, two-, three- and four-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":113207,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":113207},"source":{"system":"sec-edgar","filing":"0001641172-25-001181","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000164117225001181/ownership.xml","form_type":"4"}},{"id":1188947,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Restricted Stock Units","published_at":"2025-03-28T16:05:16.000Z","date":"2025-03-26","kind":"grant","planned":false,"acquired":true,"shares":188679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the restricted stock units will vest on each of the one-, two-, three- and four-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"25% of the restricted stock units will vest on each of the one-, two-, three- and four-year anniversaries, respectively, of the effective date of grant subject to continuous service through the applicable vesting date."}],"balance_after":188679,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":188679},"source":{"system":"sec-edgar","filing":"0001641172-25-001179","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000164117225001179/ownership.xml","form_type":"4"}},{"id":1274399,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T22:00:15.000Z","date":"2025-02-07","kind":"other","planned":false,"acquired":true,"shares":385814,"price":2.05,"value":790918.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a registered direct offering pursuant to that certain Securities Purchase Agreement, dated as of February 7, 2025, by and among the Issuer and the investors signatory thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":3258485,"source":{"system":"sec-edgar","filing":"0001493152-25-005942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225005942/ownership.xml","form_type":"4"}},{"id":1274398,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T22:00:15.000Z","date":"2025-02-07","kind":"purchase","planned":false,"acquired":true,"shares":1077600,"price":2.05,"value":2209080.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of February 7, 2025, by and among the Issuer and the investors signatory thereto."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":2872671,"source":{"system":"sec-edgar","filing":"0001493152-25-005942","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225005942/ownership.xml","form_type":"4"}},{"id":1274328,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, no par value","published_at":"2025-02-11T19:00:32.000Z","date":"2025-02-07","kind":"purchase","planned":false,"acquired":true,"shares":97561,"price":2.05,"value":200000.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of February 7, 2025, by and among the Issuer and the investors signatory thereto."}],"balance_after":151231,"source":{"system":"sec-edgar","filing":"0001493152-25-005978","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315225005978/ownership.xml","form_type":"4"}},{"id":1276285,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T01:43:04.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with the Issuer pursuant to which Broadwood Partners agreed to acquire 4,505,488 shares of Common Shares, from the Issuer in a private placement for a total purchase price of $9,236,250, or $2.05 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":11410100,"source":{"system":"sec-edgar","filing":"0000919574-25-000922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957425000922/ownership.xml","form_type":"4"}},{"id":1276284,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T01:43:04.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":4505488,"price":2.05,"value":9236250.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with the Issuer pursuant to which Broadwood Partners agreed to acquire 4,505,488 shares of Common Shares, from the Issuer in a private placement for a total purchase price of $9,236,250, or $2.05 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with the Issuer pursuant to which Broadwood Partners agreed to acquire 4,505,488 shares of Common Shares, from the Issuer in a private placement for a total purchase price of $9,236,250, or $2.05 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":11410100,"source":{"system":"sec-edgar","filing":"0000919574-25-000922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957425000922/ownership.xml","form_type":"4"}},{"id":1276283,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T01:43:04.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 660,207 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $1,353,424, or $2.05 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6904612,"source":{"system":"sec-edgar","filing":"0000919574-25-000922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957425000922/ownership.xml","form_type":"4"}},{"id":1276282,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-11T01:43:04.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":660207,"price":2.05,"value":1353424.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 660,207 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $1,353,424, or $2.05 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On February 6, 2025, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 660,207 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a registered direct offering for a total purchase price of $1,353,424, or $2.05 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6904612,"source":{"system":"sec-edgar","filing":"0000919574-25-000922","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957425000922/ownership.xml","form_type":"4"}},{"id":1285423,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-04T21:45:27.000Z","date":"2025-02-04","kind":"purchase","planned":false,"acquired":true,"shares":25,"price":2.02,"value":50.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1795071,"source":{"system":"sec-edgar","filing":"0001493152-25-004871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225004871/ownership.xml","form_type":"4"}},{"id":1285422,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-02-04T21:45:27.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":890,"price":2.01,"value":1788.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1795046,"source":{"system":"sec-edgar","filing":"0001493152-25-004871","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225004871/ownership.xml","form_type":"4"}},{"id":1289812,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-01-31T22:00:11.000Z","date":"2025-01-30","kind":"purchase","planned":false,"acquired":true,"shares":318,"price":2.01,"value":639.18,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1794156,"source":{"system":"sec-edgar","filing":"0001493152-25-004470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225004470/ownership.xml","form_type":"4"}},{"id":1289811,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-01-31T22:00:11.000Z","date":"2025-01-29","kind":"purchase","planned":false,"acquired":true,"shares":3880,"price":2.01,"value":7798.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1793838,"source":{"system":"sec-edgar","filing":"0001493152-25-004470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225004470/ownership.xml","form_type":"4"}},{"id":1302807,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-01-15T22:00:16.000Z","date":"2025-01-14","kind":"purchase","planned":false,"acquired":true,"shares":10286,"price":2.15,"value":22114.9,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1789958,"source":{"system":"sec-edgar","filing":"0001493152-25-002410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225002410/ownership.xml","form_type":"4"}},{"id":1302806,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-01-15T22:00:16.000Z","date":"2025-01-14","kind":"purchase","planned":false,"acquired":true,"shares":100,"price":2.08,"value":208.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1779672,"source":{"system":"sec-edgar","filing":"0001493152-25-002410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225002410/ownership.xml","form_type":"4"}},{"id":1302805,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2025-01-15T22:00:16.000Z","date":"2025-01-13","kind":"purchase","planned":false,"acquired":true,"shares":5669,"price":2.08,"value":11791.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1779572,"source":{"system":"sec-edgar","filing":"0001493152-25-002410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315225002410/ownership.xml","form_type":"4"}},{"id":1321090,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":23034,"kind":"person","name":"SMITH PATRICK W","position":1,"cik":"0001167028","reported_name":"SMITH PATRICK W","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-12-28T02:49:20.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":90219,"price":2.13,"value":192166.47,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares of common stock reported herein are directly held by PATRICK W SMITH TTEE THE SMITH IRREVOCABLE TRUST U/A DTD 05/01/2015 (the \"Trust\"). As the trustee of the Trust, the Reporting Person may be deemed to beneficially own the securities held by the Trust."}],"balance_after":1773903,"source":{"system":"sec-edgar","filing":"0001493152-24-052334","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1167028/000149315224052334/ownership.xml","form_type":"4"}},{"id":1321608,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-12-26T23:17:58.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":12500,"price":2.108,"value":26350.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price of $2.1080 per share represents a weighted average of prices ranging from $2.1000 to $2.1300 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":81554,"source":{"system":"sec-edgar","filing":"0001493152-24-052168","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315224052168/ownership.xml","form_type":"4"}},{"id":1339296,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, no par value","published_at":"2024-12-09T08:00:20.000Z","date":"2024-12-05","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":2.29,"value":45800.0,"ownership":{"direct":true},"balance_after":53670,"source":{"system":"sec-edgar","filing":"0001493152-24-049195","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224049195/ownership.xml","form_type":"4"}},{"id":1386812,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-15T16:15:18.000Z","date":"2024-10-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"See Exhibit 99 attached to the Prior Form 4 which is incorporated by reference herein."},{"field":"date","element":"transactionDate","label":"F1","text":"As previously disclosed in the Form 4 filed by the Reporting Person on June 24, 2024 (the \"Prior Form 4\"), the derivative securities were granted on June 20, 2024 (the \"Grant Date\"), but such award was subject to stockholder approval of an increase in the number of shares available for issuance under the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan. Such stockholder approval was obtained on October 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"See Exhibit 99 attached to the Prior Form 4 which is incorporated by reference herein."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"See Exhibit 99 attached to the Prior Form 4 which is incorporated by reference herein."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-041131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224041131/ownership.xml","form_type":"4"}},{"id":1386811,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options to Purchase Common Stock","published_at":"2024-10-15T16:15:18.000Z","date":"2024-10-11","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"As previously disclosed in the Form 4 filed by the Reporting Person on June 24, 2024 (the \"Prior Form 4\"), the derivative securities were granted on June 20, 2024 (the \"Grant Date\"), but such award was subject to stockholder approval of an increase in the number of shares available for issuance under the Oncocyte Corporation Amended and Restated 2018 Equity Incentive Plan. Such stockholder approval was obtained on October 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a subsidiary of the Issuer from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":2.87,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-24-041131","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224041131/ownership.xml","form_type":"4"}},{"id":1390681,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-10-04T23:00:42.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 2, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 1,315,339 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $3,877,619.38, or $2.948 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6244405,"source":{"system":"sec-edgar","filing":"0000919574-24-005764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424005764/ownership.xml","form_type":"4"}},{"id":1390680,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-10-04T23:00:42.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":1315339,"price":2.948,"value":3877619.372,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On October 2, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 1,315,339 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $3,877,619.38, or $2.948 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On October 2, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 1,315,339 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $3,877,619.38, or $2.948 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6244405,"source":{"system":"sec-edgar","filing":"0000919574-24-005764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424005764/ownership.xml","form_type":"4"}},{"id":1390918,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, no par value","published_at":"2024-10-04T19:40:56.000Z","date":"2024-10-02","kind":"purchase","planned":false,"acquired":true,"shares":33670,"price":2.97,"value":99999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a private placement pursuant to that certain Securities Purchase Agreement, dated as of October 2, 2024, by and among the Issuer and the investors signatory thereto."}],"balance_after":33670,"source":{"system":"sec-edgar","filing":"0001493152-24-039603","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224039603/ownership.xml","form_type":"4"}},{"id":1459800,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-04T01:00:09.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":2.95,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-24-026274","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315224026274/ownership.xml","form_type":"4"}},{"id":1459878,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-04T01:00:07.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":2.95,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-24-026273","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000149315224026273/ownership.xml","form_type":"4"}},{"id":1459627,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-07-04T01:00:06.000Z","date":"2024-07-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":2.95,"expiration_date":"2034-07-01","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-24-026272","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000149315224026272/ownership.xml","form_type":"4"}},{"id":1470997,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-06-24T16:49:33.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"See Exhibit 99 attached hereto."},{"field":"date","element":"transactionDate","label":"F1","text":"Granted on June 20, 2024 (the \"Grant Date\"), but such award is subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Following such shareholder approval, an additional Form 4 will be filed with respect to the grant in accordance with pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"See Exhibit 99 attached hereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"See Exhibit 99 attached hereto."}],"balance_after":300000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001493152-24-024981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224024981/ownership.xml","form_type":"4"}},{"id":1470996,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55366,"kind":"person","name":"James Andrea S.","position":1,"cik":"0002027010","reported_name":"James Andrea S.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Option to Purchase Common Stock","published_at":"2024-06-24T16:49:33.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Granted on June 20, 2024 (the \"Grant Date\"), but such award is subject to shareholder approval of an increase in the number of shares available for issuance under the Oncocyte 2018 Equity Incentive Plan. Following such shareholder approval, an additional Form 4 will be filed with respect to the grant in accordance with pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a Subsidiary from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Option shall vest as follows, subject to the Reporting Person's continued compliance with any restrictive covenants by which the Reporting Person may be bound and continuous service as an employee of the Issuer or a Subsidiary from June 17, 2024, through the applicable vesting date: (A) twenty-five percent (25%) of the shares subject to the Option will vest and thereby become exercisable upon the one-year anniversary of the Grant Date, and (B) 75% of the shares subject to the Option will vest in thirty-six (36) substantially equal monthly installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":2.87,"underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001493152-24-024981","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2027010/000149315224024981/ownership.xml","form_type":"4"}},{"id":1505054,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr Dir., Cntlr, PAO, Int PFO"}}],"security":"Option to Purchase Common Stock","published_at":"2024-05-22T21:18:24.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":10000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001493152-24-021055","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315224021055/ownership.xml","form_type":"4"}},{"id":1505354,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2024-05-22T20:58:41.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":20000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001493152-24-021049","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315224021049/ownership.xml","form_type":"4"}},{"id":1505770,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Option to Purchase Common Stock","published_at":"2024-05-22T16:56:24.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date."}],"balance_after":90000,"derivative":{"exercise_price":2.76,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-24-021047","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315224021047/ownership.xml","form_type":"4"}},{"id":1541807,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-15T23:21:50.000Z","date":"2024-04-15","kind":"other","planned":false,"acquired":false,"shares":0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":30.6,"underlying":"Common Stock","underlying_shares":107488},"source":{"system":"sec-edgar","filing":"0000919574-24-002558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424002558/ownership.xml","form_type":"4"}},{"id":1541806,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-04-15T23:21:50.000Z","date":"2024-04-15","kind":"other","planned":false,"acquired":false,"shares":2941.1765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On April 15, 2024, the Issuer mandatorily redeemed all of the 2,941.1765 shares of Series A Convertible Preferred Stock of the Issuer (the \"Series A Shares\") previously owned by Broadwood Partners in accordance with the terms of the Securities Purchase Agreement with the Issuer to which Broadwood Partners acquired the Series A Shares (the \"Series A Purchase Agreement\"). Pursuant to the Series A Purchase Agreement, Broadwood Partners received $3,289,144.18, or $1,118.30902 per Series A Share, in redemption proceeds attributable to the Issuer's mandatory redemption. The Series A Shares were convertible at the time of the Issuer's mandatory redemption"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":30.6,"underlying":"Common Stock","underlying_shares":107488},"source":{"system":"sec-edgar","filing":"0000919574-24-002558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424002558/ownership.xml","form_type":"4"}},{"id":1541805,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-04-15T23:21:50.000Z","date":"2024-04-11","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On April 11, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 2,420,000 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $7,057,688, or $2.9164 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4929066,"source":{"system":"sec-edgar","filing":"0000919574-24-002558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424002558/ownership.xml","form_type":"4"}},{"id":1541804,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-04-15T23:21:50.000Z","date":"2024-04-11","kind":"purchase","planned":false,"acquired":true,"shares":2420000,"price":2.9164,"value":7057688.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On April 11, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 2,420,000 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $7,057,688, or $2.9164 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 11, 2024, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 2,420,000 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in a private placement for a total purchase price of $7,057,688, or $2.9164 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. (\"Broadwood Capital\"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4929066,"source":{"system":"sec-edgar","filing":"0000919574-24-002558","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957424002558/ownership.xml","form_type":"4"}},{"id":1541859,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2024-04-15T10:02:28.000Z","date":"2024-04-11","kind":"purchase","planned":false,"acquired":true,"shares":33898,"price":2.95,"value":99999.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock, no par value (\"Common Stock\"), purchased by the Reporting Person from the Issuer in a private offering."}],"balance_after":69054,"source":{"system":"sec-edgar","filing":"0001493152-24-014509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315224014509/ownership.xml","form_type":"4"}},{"id":1542023,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Common Stock, no par value","published_at":"2024-04-15T06:04:01.000Z","date":"2024-04-11","kind":"purchase","planned":false,"acquired":true,"shares":3390,"price":2.95,"value":10000.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects shares of the Issuer's common stock, no par value, purchased by the Reporting Person from the Issuer in a private offering."}],"balance_after":3505,"source":{"system":"sec-edgar","filing":"0001493152-24-014512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315224014512/ownership.xml","form_type":"4"}},{"id":1760966,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55283,"kind":"person","name":"Liu James Yang","position":1,"cik":"0001944774","reported_name":"Liu James Yang","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr Dir Controller PAO Int PFO"}}],"security":"Option to Purchase Common Stock","published_at":"2023-10-12T20:30:57.000Z","date":"2023-10-10","kind":"grant","planned":false,"acquired":true,"shares":8482,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date."}],"balance_after":8482,"derivative":{"exercise_price":3.11,"expiration_date":"2033-10-10","underlying":"Common Stock","underlying_shares":8482},"source":{"system":"sec-edgar","filing":"0001493152-23-037054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000149315223037054/ownership.xml","form_type":"4"}},{"id":1804015,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Option to Purchase Common Stock","published_at":"2023-08-17T18:57:33.000Z","date":"2023-08-15","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025."}],"balance_after":40000,"derivative":{"exercise_price":3.34,"expiration_date":"2033-08-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001493152-23-029347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315223029347/ownership.xml","form_type":"4"}},{"id":1839264,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Warrants to Purchase Common Stock","published_at":"2023-07-03T22:00:08.000Z","date":"2023-06-30","kind":"other","planned":false,"acquired":false,"shares":3564728,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F8","text":"Represents warrants to purchase shares of Common Stock (the \"Warrants\") that were distributed by the Halle Fund on a pro rata basis to its members (the \"Halle Warrant Distribution\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The Warrants are currently exercisable, subject to a beneficial ownership limitation of 4.99%."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Represents Warrants directly beneficially owned by the Halle Fund. The Reporting Person is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund."}],"balance_after":0,"derivative":{"exercise_price":1.53,"expiration_date":"2027-04-19","underlying":"Common Stock","underlying_shares":3001876},"source":{"system":"sec-edgar","filing":"0000899243-23-016837","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000089924323016837/doc4.xml","form_type":"4"}},{"id":1839263,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111691,"kind":"person","name":"Gutfreund John Peter","position":1,"cik":"0001940797","reported_name":"Gutfreund John Peter","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock, no par value","published_at":"2023-07-03T22:00:08.000Z","date":"2023-06-30","kind":"other","planned":false,"acquired":false,"shares":3085047,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of Common Stock of Oncocyte Corporation (the \"Issuer\"), no par value (the \"Common Stock\"), that were distributed by Halle Special Situations Fund LLC (the \"Halle Fund\") on a pro rata basis to its members (the \"Halle Common Stock Distribution\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares of Common Stock directly beneficially owned by the Halle Fund. John Peter Gutfreund (the \"Reporting Person\") is the investment manager and a control person of Halle Capital Partners GP LLC, the managing member of the Halle Fund. In such capacity, the Reporting Person may be deemed to beneficially own any securities directly owned by the Halle Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person states that neither the filing of this statement nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), or otherwise, the beneficial owner of any securities covered by this statement. The Reporting Person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of the Reporting Person in such securities."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-016837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1642380/000089924323016837/doc4.xml","form_type":"4"}},{"id":1843438,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-28T01:30:20.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":135000,"derivative":{"exercise_price":0.2,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0001493152-23-022668","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315223022668/ownership.xml","form_type":"4"}},{"id":1843437,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32107,"kind":"person","name":"Arno Andrew","position":1,"cik":"0001472122","reported_name":"Arno Andrew","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-06-28T01:30:20.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":703133,"source":{"system":"sec-edgar","filing":"0001493152-23-022668","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472122/000149315223022668/ownership.xml","form_type":"4"}},{"id":1843441,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-28T01:30:16.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":90000,"derivative":{"exercise_price":0.2,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-23-022669","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000149315223022669/ownership.xml","form_type":"4"}},{"id":1843440,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32109,"kind":"person","name":"Last Andrew J.","position":1,"cik":"0001485088","reported_name":"Last Andrew J.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-06-28T01:30:16.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":90170,"source":{"system":"sec-edgar","filing":"0001493152-23-022669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1485088/000149315223022669/ownership.xml","form_type":"4"}},{"id":1843378,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-28T01:30:09.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":112500,"derivative":{"exercise_price":0.2,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001493152-23-022666","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000149315223022666/ownership.xml","form_type":"4"}},{"id":1843377,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":32077,"kind":"person","name":"SILVERMAN LOU","position":1,"cik":"0001249935","reported_name":"SILVERMAN LOU","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-06-28T01:30:09.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":31270,"source":{"system":"sec-edgar","filing":"0001493152-23-022666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1249935/000149315223022666/ownership.xml","form_type":"4"}},{"id":1843372,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-27T21:30:12.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":90000,"derivative":{"exercise_price":0.2,"expiration_date":"2033-06-23","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001493152-23-022667","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1229339/000149315223022667/ownership.xml","form_type":"4"}},{"id":1843371,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-06-27T21:30:12.000Z","date":"2023-06-23","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders."}],"balance_after":489111,"source":{"system":"sec-edgar","filing":"0001493152-23-022667","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229339/000149315223022667/ownership.xml","form_type":"4"}},{"id":1854089,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":111714,"kind":"person","name":"KINGSLEY ALFRED D","position":1,"cik":"0001229339","reported_name":"KINGSLEY ALFRED D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-06-15T20:13:04.000Z","date":"2023-06-14","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.2149,"value":6447.0,"ownership":{"direct":true},"balance_after":469111,"source":{"system":"sec-edgar","filing":"0001493152-23-021531","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1229339/000149315223021531/ownership.xml","form_type":"4"}},{"id":1857489,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-13T16:05:32.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":800000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025."}],"balance_after":800000,"derivative":{"exercise_price":0.2132,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001493152-23-021059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315223021059/ownership.xml","form_type":"4"}},{"id":1857488,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":55352,"kind":"person","name":"Riggs Josh","position":1,"cik":"0001956391","reported_name":"Riggs Josh","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and President"}}],"security":"Option to Purchase Common Stock","published_at":"2023-06-13T16:05:32.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date."}],"balance_after":350000,"derivative":{"exercise_price":0.2132,"expiration_date":"2033-06-09","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001493152-23-021059","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1956391/000149315223021059/ownership.xml","form_type":"4"}},{"id":1917869,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":98000,"kind":"organization","name":"PURA VIDA INVESTMENTS, LLC","position":1,"cik":"0001590144","reported_name":"PURA VIDA INVESTMENTS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114373,"kind":"person","name":"Kamen Efrem","position":2,"cik":"0001789193","reported_name":"Kamen Efrem","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant to purchase common stock","published_at":"2023-04-18T22:49:49.000Z","date":"2023-03-06","kind":"other","planned":false,"acquired":false,"shares":440964,"ownership":{"direct":false,"nature":"By the Managed Accounts."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore the warrants and the underlying common stock are no longer deemed beneficially owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"See footnotes 3 and 4."}],"balance_after":517245,"derivative":{"exercise_price":1.53,"exercise_date":"2022-04-19","expiration_date":"2027-04-19","underlying":"Common Stock","underlying_shares":440964},"source":{"system":"sec-edgar","filing":"0001209191-23-024720","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1590144/000120919123024720/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-08"}},{"id":1917868,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":98000,"kind":"organization","name":"PURA VIDA INVESTMENTS, LLC","position":1,"cik":"0001590144","reported_name":"PURA VIDA INVESTMENTS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114373,"kind":"person","name":"Kamen Efrem","position":2,"cik":"0001789193","reported_name":"Kamen Efrem","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-18T22:49:49.000Z","date":"2023-03-06","kind":"other","planned":false,"acquired":false,"shares":3890111,"ownership":{"direct":false,"nature":"By the Managed Accounts."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As of March 6, 2023, the Reporting Persons no longer have voting and dispositive power for certain Managed Accounts and therefore such shares are no longer deemed beneficially owned by the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Securities reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the \"Retirement Trust\") and certain separately managed accounts (the \"Managed Accounts\" and collectively, the \"Client Accounts\"). Pura Vida Investments, LLC (\"PVI\") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":4589571,"source":{"system":"sec-edgar","filing":"0001209191-23-024720","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590144/000120919123024720/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-08"}},{"id":1922803,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":98000,"kind":"organization","name":"PURA VIDA INVESTMENTS, LLC","position":1,"cik":"0001590144","reported_name":"PURA VIDA INVESTMENTS, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":114373,"kind":"person","name":"Kamen Efrem","position":2,"cik":"0001789193","reported_name":"Kamen Efrem","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-04-07T21:12:10.000Z","date":"2023-04-05","kind":"purchase","planned":false,"acquired":true,"shares":663000,"price":0.3017,"value":200027.1,"ownership":{"direct":false,"nature":"By Pura Vida Master Fund, Ltd."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares reported herein are owned by Pura Vida Master Fund, Ltd., Pura Vida X Fund LP, and Lockheed Martin Corporation Master Retirement Trust (the \"Retirement Trust\"), and certain separately managed accounts (the \"Managed Accounts\" and collectively, the \"Client Accounts\"). Pura Vida Investments, LLC (\"PVI\") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the securities owned directly by the Client Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the securities for purposes of Sections 13 and 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of the Reporting Person's pecuniary interest therein, if any."}],"balance_after":8090202,"source":{"system":"sec-edgar","filing":"0001209191-23-023828","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590144/000120919123023828/doc4.xml","form_type":"4"}},{"id":1924747,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-04-06T01:35:33.000Z","date":"2023-04-03","kind":"purchase","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On April 3, 2023, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 26,827,638 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in its registered direct offering for a total purchase price of $8,093,361.84, or $0.30168 per Common Share."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. (\"Broadwood Capital\") as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":50181335,"source":{"system":"sec-edgar","filing":"0000919574-23-002420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957423002420/ownership.xml","form_type":"4"}},{"id":1924746,"issuer":{"id":6631,"kind":"organization","name":"Insight Molecular Diagnostics Inc."},"owners":[{"id":51158,"kind":"organization","name":"BROADWOOD PARTNERS, L.P.","position":1,"cik":"0001278386","reported_name":"BROADWOOD PARTNERS, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51159,"kind":"organization","name":"BROADWOOD CAPITAL INC","position":2,"cik":"0001278387","reported_name":"BROADWOOD CAPITAL INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":33406,"kind":"person","name":"Bradsher Neal C","position":3,"cik":"0001278388","reported_name":"BRADSHER NEAL C","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, no par value","published_at":"2023-04-06T01:35:33.000Z","date":"2023-04-03","kind":"purchase","planned":false,"acquired":true,"shares":26827638,"price":0.3017,"value":8093898.3846,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"On April 3, 2023, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 26,827,638 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in its registered direct offering for a total purchase price of $8,093,361.84, or $0.30168 per Common Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On April 3, 2023, Broadwood Partners entered into a Securities Purchase Agreement with Oncocyte Corporation (the \"Issuer\") pursuant to which Broadwood Partners agreed to acquire 26,827,638 shares of the Issuer's Common Stock, no par value (the \"Common Shares\"), from the Issuer in its registered direct offering for a total purchase price of $8,093,361.84, or $0.30168 per Common Share."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities are directly owned by Broadwood Partners, L.P. (\"Broadwood Partners\") and may be deemed to be indirectly beneficially owned by: (i) Broadwood Capital, Inc. (\"Broadwood Capital\") as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":50181335,"source":{"system":"sec-edgar","filing":"0000919574-23-002420","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1278386/000091957423002420/ownership.xml","form_type":"4"}}],"next_cursor":"2023-04-06T01:35:33.000000Z,1924746"}